Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine proposal comment period "immediate" suspension requested in letter to FDA.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRINE PROPOSAL COMMENT PERIOD "IMMEDIATE" SUSPENSION REQUESTED by Starlight International and Nutraceutical Corp. outside counsel Hyman, Phelps & McNamara in an Oct. 3 letter to FDA Lead Deputy Commissioner Michael Friedman, MD. The firm is asking that the comment period on the agency's June 4 proposal establishing dosage restrictions and label warnings for dietary supplements containing ephedrine alkaloids be closed again immediately to allow the review of recent FDA changes to the administrative record.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel